ICAR

Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

Retrieved on: 
Monday, March 21, 2022
Regulation, NASDAQ, Investor, Conference, Antiviral Research, Severe acute respiratory syndrome coronavirus 2, Regulation Fair Disclosure, ICAR, Disclosure, COVID-19, Trinidad and Tobago Securities and Exchange Commission, GLOBE, U.S. Securities and Exchange Commission, Infection, International Conference on Emerging Infectious Diseases, PRDS, Security (finance), Pharmaceutical industry

Details of Pardes oral presentation:

Key Points: 
  • Details of Pardes oral presentation:
    Registered attendees will be able to view the presentation session on the ICAR virtual platform, which will be available live or on-demand through April 25, 2022.
  • Pardes Biosciences is a clinical-stage biopharmaceuticalcompany created to help solve pandemic-sized problems, starting with COVID-19.
  • Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure).
  • Accordingly, investors should monitor Pardes Biosciences Investors website, in addition to following Pardes press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)

Retrieved on: 
Monday, March 21, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, HCV, Cancer, Therapy, Cytokine, Population, Degenerative disease, Clinical trial, Patient, Orthornavirae, Conference, Antiviral Research, RNA, Severe acute respiratory syndrome coronavirus 2, Administration, Â, View, Safety, ICAR, NF, Inflammation, Coronavirus, Replicon, RSV, TLR7, International Conference on Emerging Infectious Diseases, IL-6, Temperature, Human coronavirus 229E, Toxicity, Vaccine, Dietary supplement, Pharmaceutical industry, PRTX007, PRIMMUNE THERAPEUTICS, PRTX007, PRIMMUNE THERAPEUTICS

Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today presented data evaluating the antiviral activity of PRTX007, a novel, small molecule toll-like receptor 7 (TLR7) specific agonist, at the International Conference on Antiviral Research (ICAR).

Key Points: 
  • Primmune Therapeutics , a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today presented data evaluating the antiviral activity of PRTX007, a novel, small molecule toll-like receptor 7 (TLR7) specific agonist, at the International Conference on Antiviral Research (ICAR).
  • PRTX007 demonstrated antiviral activity in both cell and murine models against RSV, as well as in cell models against SARS-CoV-2 and seven other RNA viruses.
  • These findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007 as a clinical candidate to treat acute viral infections and for stockpiling for pandemic preparedness.
  • Primmune is also evaluating the safety and tolerability of PRTX007 in an ongoing first-in-human clinical trial.

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, March 10, 2022
VBR, C1-inhibitor, U.S. Securities and Exchange Commission, Securities Act of 1933, Antiviral Research, Therapy, HBV, Degenerative disease, Report, AbbVie, Program, Safety, Development, Drug Quality and Security Act, Assembly, ICAR, Asilomar International Conference on Climate Intervention Technologies, Sumathi Best Television Current Reporting Award, DNA, Securities Exchange Act of 1934, GLOBE, Doctor of Philosophy, Patient, SEC, Research, ATM, Annual report, Conference, MD, Treatment, BeiGene, 2021 Essex County Council election, CccDNA, Liver, Initiate, Acquisition, COVID-19, Hepatitis B virus, AO, SAN, AASLD, Pharmaceutical industry, Allergan

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.
  • We look forward to introducing the first of these during a web event at the end this month.
  • Revenues from collaborative research were $6.3 million for the year ended December 31, 2021, compared to $79.1 million in 2020.
  • Research and development expenses were $68.5 million for the year ended December 31, 2021, compared to $106.8 million in 2020.

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research

Retrieved on: 
Thursday, February 24, 2022
GLOBE, Lung, EC50, University of North Carolina at Greensboro, Kruskal–Wallis one-way analysis of variance, Innovation, Virus, NASDAQ, University, ICAR, UNC Eshelman School of Pharmacy, Safety, Combination therapy, Respiratory disease, Severe acute respiratory syndrome coronavirus 2, International Conference on Emerging Infectious Diseases, BARDA, Antiviral Research, Conference, Patient, Epithelium, CMX521, Degenerative disease, Infection, Doctor of Philosophy, Chapel Hill, Pharmaceutical industry, Pharmacy

This agent is particularly interesting in that it has demonstrated an attractive safety profile in a prior Phase 1 dose escalation trial in healthy volunteers.

Key Points: 
  • This agent is particularly interesting in that it has demonstrated an attractive safety profile in a prior Phase 1 dose escalation trial in healthy volunteers.
  • In vitro, CMX521 was shown to inhibit SARS-CoV-2 replication in primary human airway epithelial cells with an average EC50 of 0.9M.
  • In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure.
  • Forward-looking statements include those relating to, among other things, the results of current and future preclinical and clinical testing of CMX521.

World Swine Vaccines Market Report 2022: Focus on Products (Recombinant, Inactivated), & Type (Pseudorabies, Porcine Circovirus Type 2) - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022
Agriculture, Natural Resources, Health, Veterinary, Pharmaceutical, CAGR, Research, Technology, Vaccine, ICAR, PCV2, ALCO RS-2, Indian Veterinary Research Institute, Urbanization, COVID-19, Virus, Porcine reproductive and respiratory syndrome virus 2, Growth, Atmosphere, Farm, Disease, PRRS, Animal Health, DNA, Health, Infection, Betaarterivirus suid 1, Industry, Classical swine fever, IVRI, PPV, Diagnosis, Miniature pig, USD, Mutation, Bareilly, Prevalence, Foot, Indian Immunologicals Limited, Investment, Awareness, Aquaculture

The "Swine Vaccines Market Size, Share & Trends Analysis Report 2021-2028" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Swine Vaccines Market Size, Share & Trends Analysis Report 2021-2028" has been added to ResearchAndMarkets.com's offering.
  • Porcine Parvovirus (PPV), Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine circovirus type 2 (PCV2), Foot & Mouth Disease, Classical Swine Fever, and others remain to be extremely prevalent diseases in pig farms affecting economic losses.
  • The COVID-19 pandemic directly or indirectly impacted the business, results of operations, and financial conditions of market players.
  • In addition, the growing investments by key players to develop advanced products for better diagnosis are likely to propel market growth.

Xinhua Silk Road: Chery's NEV QQ Ice Cream unveiled at a cultural festival in Wuhu, Anhui

Retrieved on: 
Tuesday, January 4, 2022
Cream, People, ICAR, Ecology, 3D, Culture, Ice cream, NEVS, NEV, Entertainment, Chery

BEIJING, Jan. 4, 2022 /PRNewswire/ -- Chery Automobile has launched its first new energy vehicle (NEV) QQ Ice Cream recently, in light of which Wuhu City of east China's Anhui Province held a cultural festival onDecember28 to not only introduce the new auto product, but also promote Wuhu's traditional culture.

Key Points: 
  • BEIJING, Jan. 4, 2022 /PRNewswire/ -- Chery Automobile has launched its first new energy vehicle (NEV) QQ Ice Cream recently, in light of which Wuhu City of east China's Anhui Province held a cultural festival onDecember28 to not only introduce the new auto product, but also promote Wuhu's traditional culture.
  • QQ Ice Cream was disclosed to the public at the opening ceremony of the cultural festival on Tuesday evening, which attracts many citizens to watch the performance such as 3D drones performance, fireworks show and light show.
  • Exhibition areas are also set at the cultural festival to showcase Wuhu's history and culture, modern technology and local brands.
  • People have the chance to watch Wuhu rice carving, pulp dyeing and other traditional folk art as well as latest sci-tech achievements such as NEVs, robots, etc.

Xinhua Silk Road: Chery's NEV QQ Ice Cream unveiled at a cultural festival in Wuhu, Anhui

Retrieved on: 
Tuesday, January 4, 2022
Cream, People, ICAR, Ecology, Multimedia, 3D, Culture, Ice cream, NEVS, NEV, Motor vehicle, Entertainment, Chery

BEIJING, Jan. 3, 2022 /PRNewswire/ -- Chery Automobile has launched its first new energy vehicle (NEV) QQ Ice Cream recently, in light of which Wuhu City of east China's Anhui Province held a cultural festival onDecember28 to not only introduce the new auto product, but also promote Wuhu's traditional culture.

Key Points: 
  • BEIJING, Jan. 3, 2022 /PRNewswire/ -- Chery Automobile has launched its first new energy vehicle (NEV) QQ Ice Cream recently, in light of which Wuhu City of east China's Anhui Province held a cultural festival onDecember28 to not only introduce the new auto product, but also promote Wuhu's traditional culture.
  • QQ Ice Cream was disclosed to the public at the opening ceremony of the cultural festival on Tuesday evening, which attracts many citizens to watch the performance such as 3D drones performance, fireworks show and light show.
  • The new car is the first model of Chery's iCar ecology with price ranging from 29,900 to 43,900 yuan, which is believed to bring green, economic and convenient driving experience.
  • Exhibition areas are also set at the cultural festival to showcase Wuhu's history and culture, modern technology and local brands.

Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting

Retrieved on: 
Friday, November 12, 2021
Gastrointestinal tract, SITC, ICAR, Epithelium, Colorectal cancer, Acar, SAN, Logic, Society, NK, Carcinoembryonic antigen, SA, CRC, Neoplasm, GLOBE, Annual general meeting, DBTL, Molecular logic gate, GATE, Toxicity, Senty Church, Immunotherapy, CEA, Colon, NOT, Cell, CAR, Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Senti Bio, a leading gene circuit company, today announced results from SENTI-401, one of its preclinical stage oncology programs, that aims to more precisely target tumors while sparing healthy cells. The poster presentation, which is on display starting today at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), describes preclinical data from SENTI-401, a Logic Gated allogeneic, chimeric antigen receptor natural killer (CAR-NK) cell therapy development program for the treatment of colorectal cancer (CRC). The results support the Company’s vision of using gene circuits to create next-generation, “smart” cell and gene therapies with computer-like logic in human cells.Targeting of tumor-associated antigens, such as carcinoembryonic antigen (CEA), can result in severe clinical toxicities due to the killing of healthy epithelial cells whose cell surfaces also express CEA. This includes toxicity risk to cells in the colon and gastrointestinal tract as well as the lungs. SENTI-401 is designed to incorporate logic gating to target and kill CEA-expressing tumor cells, while preventing the killing of CEA-expressing healthy epithelial cells. The SENTI-401 NOT GATE pairs a CEA-targeting activating-CAR (aCAR) with an inhibitory-CAR (iCAR) that recognizes a safety antigen (SA) uniquely expressed in certain healthy gastrointestinal and lung epithelial cells. The SA was identified and validated through Senti Bio’s proprietary Bioinformatics-Driven Antigen Pairing (B-DAP) discovery platform. The poster highlights the SENTI-401 development program’s NOT GATE gene circuit technology as follows:

Key Points: 
  • The poster presentation, which is on display starting today at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), describes preclinical data from SENTI-401, a Logic Gated allogeneic, chimeric antigen receptor natural killer (CAR-NK) cell therapy development program for the treatment of colorectal cancer (CRC).
  • The results support the Companys vision of using gene circuits to create next-generation, smart cell and gene therapies with computer-like logic in human cells.
  • This includes toxicity risk to cells in the colon and gastrointestinal tract as well as the lungs.
  • SENTI-401 is designed to incorporate logic gating to target and kill CEA-expressing tumor cells, while preventing the killing of CEA-expressing healthy epithelial cells.

RenaissanceRe’s 15th Risk Mitigation Leadership Forum Focuses on Community Solutions to Advance Climate Change Resiliency Globally

Retrieved on: 
Thursday, September 30, 2021
Professional Services, Insurance, Environment, Finance, Gainer, Insurance, Assistant, RNR, Climate change, ICAR, Public sector, Disaster, Solution, Nature, Emergency management, Forum, Senior, Business, CEO, United Kingdom, Weather, Private sector, Comprehensive, Virginia Department of Corrections, Awareness, Science, Eastern Sudan States Coordinating Council, Safety, FEMA, Movement, NYSE, City, Risk management, Management

RenaissanceRe (NYSE: RNR) hosted thought leaders, risk scientists, and community experts at the Protecting Communities from Climate Change: Using Portsmouth, Virginia to Kickstart Global Solutions risk mitigation leadership forum.

Key Points: 
  • RenaissanceRe (NYSE: RNR) hosted thought leaders, risk scientists, and community experts at the Protecting Communities from Climate Change: Using Portsmouth, Virginia to Kickstart Global Solutions risk mitigation leadership forum.
  • The 15th annual forum sought to advance risk mitigation efforts and awareness, support community preparedness and resilience, and strategize how to better prepare for, and respond to, natural catastrophes.
  • Climate change is making extreme weather events more frequent and severe and is an urgent issue for communities, businesses and governments.
  • In 2008, RenaissanceRe created its award-winning Risk Mitigation Leadership Forum series to advance the disaster safety movement in a collaborative way and develop strategies that foster community resiliency.

asTech® Continues To Lead Diagnostic Solutions With The Provision Of The First Ever Official OEM Scan Report

Retrieved on: 
Thursday, September 23, 2021
Philosophy, ASE, IOS, ICAR, Master, Kinderhook, OEM, Multimedia, Kinderhook Industries, Android, LLC, Growth, Technology, Calibration, Investment, Light, Industry, Online shopping, Medical device

"The delivery of the original OEM scan report will provide our customers with an additional layer of confidence and transparency so they can remain focused on properly repairing today's complex vehicles."

Key Points: 
  • "The delivery of the original OEM scan report will provide our customers with an additional layer of confidence and transparency so they can remain focused on properly repairing today's complex vehicles."
  • asTech is a global leader in the provision of remote diagnostic solutions with a library of over 1,000 OEM scan tools and growing.
  • Now following an asTech remote OEM scan, customers will have access to a copy of the official OEM tool report.
  • asTech is the leading provider of remote diagnostic solutions and services to the collision industry.